Raj Bhayadia

About

My work is centered on clinically relevant, patient-oriented research in the field of tumor disease with a special emphasis in hemato-oncology. My research group has pioneered in the development and pre-clinical testing of novel therapeutic agents and combinatorial therapies for hemato-oncological malignancies. In addition we aim to advance the field by identifying and validating biomarkers for early diagnosis, prognosis and potential treatment in blood cancers. Our ambition is to bridge the gap between laboratory discovery and clinical applications to ensure that scientific advancements translate into tangible benefits for patients suffering from hematological malignancies.

Employment

• Goethe-Universität Frankfurt am Main Junior Group Leader
  2021 - Present
• Martin-Luther-Universität Halle-Wittenberg Post-doc
  2019 - 2021

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome–associated myeloid leukemia
  Blood Advances 2026 DOI: 10.1182/bloodadvances.2025018830
  +Save
• Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia
  Leukemia 2026 DOI: 10.1038/s41375-026-03040-y
  +Save
• CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
  Nature Communications 2024 DOI: 10.1038/s41467-024-52388-1
  +Save
• DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia
  2024 DOI: 10.1101/2024.08.30.608947
  +Save
• PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia
  Leukemia 2023 DOI: 10.1038/s41375-023-02041-5
  +Save
• Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15
  iScience 2023 DOI: 10.1016/j.isci.2023.107844
  +Save
• Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias
  Leukemia 2023 DOI: 10.1038/s41375-023-01937-6
  +Save
• RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia
  Blood 2023 DOI: 10.1182/blood.2022017619
  +Save
• The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis
  Blood 2022 DOI: 10.1182/blood.2021012231
  +Save
• Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core
  Leukemia 2022 DOI: 10.1038/s41375-022-01603-3
  +Save